Annual CFI
-$299.48 M
-$260.23 M-662.86%
December 31, 2024
Summary
- As of March 12, 2025, PTGX annual cash flow from investing activities is -$299.48 million, with the most recent change of -$260.23 million (-662.86%) on December 31, 2024.
- During the last 3 years, PTGX annual CFI has fallen by -$283.62 million (-1788.29%).
- PTGX annual CFI is now -427.42% below its all-time high of $91.47 million, reached on December 31, 2022.
Performance
PTGX Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFI
-$8.72 M
+$199.99 M+95.82%
December 31, 2024
Summary
- As of March 12, 2025, PTGX quarterly cash flow from investing activities is -$8.72 million, with the most recent change of +$199.99 million (+95.82%) on December 31, 2024.
- Over the past year, PTGX quarterly CFI has increased by +$199.99 million (+95.82%).
- PTGX quarterly CFI is now -115.23% below its all-time high of $57.27 million, reached on September 30, 2022.
Performance
PTGX Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFI
-$299.48 M
+$52.56 M+14.93%
December 31, 2024
Summary
- As of March 12, 2025, PTGX TTM cash flow from investing activities is -$299.48 million, with the most recent change of +$52.56 million (+14.93%) on December 31, 2024.
- Over the past year, PTGX TTM CFI has increased by +$52.56 million (+14.93%).
- PTGX TTM CFI is now -359.52% below its all-time high of $115.40 million, reached on September 30, 2022.
Performance
PTGX TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Investing Formula
CFI = Cash Inflows from Investments − Cash Outflows for Investments
PTGX Cash From Investing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -662.9% | +95.8% | +14.9% |
| 3 y3 years | -1788.3% | +95.8% | +14.9% |
| 5 y5 years | -457.6% | +95.8% | +14.9% |
PTGX Cash From Investing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -427.4% | at low | -115.2% | +95.8% | -359.5% | +14.9% |
| 5 y | 5-year | -427.4% | at low | -115.2% | +95.8% | -359.5% | +14.9% |
| alltime | all time | -427.4% | at low | -115.2% | +95.8% | -359.5% | +14.9% |
Protagonist Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$299.48 M(+662.9%) | -$8.72 M(-95.8%) | -$299.48 M(-14.9%) |
| Sep 2024 | - | -$208.71 M(+136.9%) | -$352.05 M(+124.4%) |
| Jun 2024 | - | -$88.12 M(-1551.5%) | -$156.89 M(+264.8%) |
| Mar 2024 | - | $6.07 M(-109.9%) | -$43.01 M(+9.6%) |
| Dec 2023 | -$39.26 M(-142.9%) | -$61.29 M(+352.0%) | -$39.26 M(-251.2%) |
| Sep 2023 | - | -$13.56 M(-152.6%) | $25.96 M(-73.2%) |
| Jun 2023 | - | $25.76 M(+162.2%) | $96.80 M(-8.5%) |
| Mar 2023 | - | $9.83 M(+149.7%) | $105.77 M(+15.6%) |
| Dec 2022 | $91.47 M(-676.7%) | $3.94 M(-93.1%) | $91.47 M(-20.7%) |
| Sep 2022 | - | $57.27 M(+64.9%) | $115.40 M(+760.0%) |
| Jun 2022 | - | $34.73 M(-876.0%) | $13.42 M(-199.1%) |
| Mar 2022 | - | -$4.48 M(-116.1%) | -$13.54 M(-14.6%) |
| Dec 2021 | -$15.86 M(-82.6%) | $27.87 M(-162.3%) | -$15.86 M(-86.6%) |
| Sep 2021 | - | -$44.71 M(-675.2%) | -$118.13 M(-7.4%) |
| Jun 2021 | - | $7.77 M(-214.4%) | -$127.54 M(-9.2%) |
| Mar 2021 | - | -$6.79 M(-90.9%) | -$140.49 M(+54.4%) |
| Dec 2020 | -$90.97 M(+69.4%) | -$74.40 M(+37.5%) | -$90.97 M(+212.4%) |
| Sep 2020 | - | -$54.12 M(+946.6%) | -$29.12 M(+313.9%) |
| Jun 2020 | - | -$5.17 M(-112.1%) | -$7.03 M(-53.4%) |
| Mar 2020 | - | $42.73 M(-440.4%) | -$15.09 M(-71.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | -$53.71 M(-2527.0%) | -$12.55 M(-60.8%) | -$53.71 M(+46.7%) |
| Sep 2019 | - | -$32.04 M(+142.3%) | -$36.61 M(-784.4%) |
| Jun 2019 | - | -$13.22 M(-421.9%) | $5.35 M(-81.0%) |
| Mar 2019 | - | $4.11 M(-9.7%) | $28.16 M(+1172.7%) |
| Dec 2018 | $2.21 M(-86.0%) | $4.55 M(-54.1%) | $2.21 M(-8.4%) |
| Sep 2018 | - | $9.92 M(+3.4%) | $2.42 M(-129.2%) |
| Jun 2018 | - | $9.59 M(-143.9%) | -$8.27 M(+73.4%) |
| Mar 2018 | - | -$21.84 M(-559.7%) | -$4.77 M(-130.2%) |
| Dec 2017 | $15.82 M(-126.7%) | $4.75 M(-715.5%) | $15.82 M(-129.7%) |
| Sep 2017 | - | -$772.00 K(-105.9%) | -$53.25 M(+9.6%) |
| Jun 2017 | - | $13.09 M(-1147.4%) | -$48.60 M(-28.2%) |
| Mar 2017 | - | -$1.25 M(-98.1%) | -$67.72 M(+14.2%) |
| Dec 2016 | -$59.33 M(+617.9%) | -$64.33 M(-1756.2%) | -$59.33 M(+1821.2%) |
| Sep 2016 | - | $3.88 M(-164.4%) | -$3.09 M(-56.4%) |
| Jun 2016 | - | -$6.03 M(-184.4%) | -$7.08 M(+537.1%) |
| Mar 2016 | - | $7.15 M(-188.4%) | -$1.11 M(-86.5%) |
| Dec 2015 | -$8.26 M(+2663.9%) | -$8.09 M(+7054.9%) | -$8.26 M(+4516.8%) |
| Sep 2015 | - | -$113.00 K(+85.2%) | -$179.00 K(+171.2%) |
| Jun 2015 | - | -$61.00 K(+1120.0%) | -$66.00 K(+1220.0%) |
| Mar 2015 | - | -$5000.00 | -$5000.00 |
| Dec 2014 | -$299.00 K | - | - |
FAQ
- What is Protagonist Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Protagonist Therapeutics?
- What is Protagonist Therapeutics annual CFI year-on-year change?
- What is Protagonist Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Protagonist Therapeutics?
- What is Protagonist Therapeutics quarterly CFI year-on-year change?
- What is Protagonist Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Protagonist Therapeutics?
- What is Protagonist Therapeutics TTM CFI year-on-year change?
What is Protagonist Therapeutics annual cash flow from investing activities?
The current annual CFI of PTGX is -$299.48 M
What is the all time high annual CFI for Protagonist Therapeutics?
Protagonist Therapeutics all-time high annual cash flow from investing activities is $91.47 M
What is Protagonist Therapeutics annual CFI year-on-year change?
Over the past year, PTGX annual cash flow from investing activities has changed by -$260.23 M (-662.86%)
What is Protagonist Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of PTGX is -$8.72 M
What is the all time high quarterly CFI for Protagonist Therapeutics?
Protagonist Therapeutics all-time high quarterly cash flow from investing activities is $57.27 M
What is Protagonist Therapeutics quarterly CFI year-on-year change?
Over the past year, PTGX quarterly cash flow from investing activities has changed by +$199.99 M (+95.82%)
What is Protagonist Therapeutics TTM cash flow from investing activities?
The current TTM CFI of PTGX is -$299.48 M
What is the all time high TTM CFI for Protagonist Therapeutics?
Protagonist Therapeutics all-time high TTM cash flow from investing activities is $115.40 M
What is Protagonist Therapeutics TTM CFI year-on-year change?
Over the past year, PTGX TTM cash flow from investing activities has changed by +$52.56 M (+14.93%)